TY - JOUR
T1 - Effects of adjunctive lacosamide on mood and quality of life in patients with epilepsy
AU - Nakhutina, Luba
AU - Kunnakkat, Saroj D.
AU - Coleman, Madeleine
AU - Lushbough, Catherine
AU - Arnedo, Vanessa
AU - Soni, Nirali
AU - Grant, Arthur C.
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/8
Y1 - 2017/8
N2 - We examined the effects of adjunctive lacosamide (LCM) on mood and quality of life (QOL) in adult patients with partial-onset seizures in a prospective, controlled, single-blind study. Patients in whom LCM was added to their AED regimen for clinical indications comprised the LCM group (n = 18), while the control group (n = 32) comprised patients on ≥ 2 AEDs with anticipated stable dosing for the duration of the study. Profile of Mood States (POMS) and QOLIE-89 were used to assess mood and QOL at enrollment and 12–16 weeks later. Adherence to LCM was measured electronically with the Medication Event Monitoring System (MEMS) and using a self-report measure. There were no significant between-group differences in age, AED load, side-effects (A–B Neurotoxicity Scale), MoCA mental status, or seizure-related factors. LCM adherence (measured by MEMS) was 70.7%. There was a significant decrease in negative mood states in the LCM group (estimated marginal mean at baseline = 49.4, at follow-up = 29.7; p = 0.02), after controlling for seizure freedom. Based on previously reported benchmarks, clinically significant change on the POMS occurred in 7 (38%) LCM patients. The effect of LCM on the overall QOL was not significant (p = 0.078). Correlation between POMS Total Mood Distress and Emotional-Wellbeing on the QOLIE-89 was significant (r = − 0.783; p = 0.01). These results suggest that LCM may have a favorable impact on mood.
AB - We examined the effects of adjunctive lacosamide (LCM) on mood and quality of life (QOL) in adult patients with partial-onset seizures in a prospective, controlled, single-blind study. Patients in whom LCM was added to their AED regimen for clinical indications comprised the LCM group (n = 18), while the control group (n = 32) comprised patients on ≥ 2 AEDs with anticipated stable dosing for the duration of the study. Profile of Mood States (POMS) and QOLIE-89 were used to assess mood and QOL at enrollment and 12–16 weeks later. Adherence to LCM was measured electronically with the Medication Event Monitoring System (MEMS) and using a self-report measure. There were no significant between-group differences in age, AED load, side-effects (A–B Neurotoxicity Scale), MoCA mental status, or seizure-related factors. LCM adherence (measured by MEMS) was 70.7%. There was a significant decrease in negative mood states in the LCM group (estimated marginal mean at baseline = 49.4, at follow-up = 29.7; p = 0.02), after controlling for seizure freedom. Based on previously reported benchmarks, clinically significant change on the POMS occurred in 7 (38%) LCM patients. The effect of LCM on the overall QOL was not significant (p = 0.078). Correlation between POMS Total Mood Distress and Emotional-Wellbeing on the QOLIE-89 was significant (r = − 0.783; p = 0.01). These results suggest that LCM may have a favorable impact on mood.
KW - Epilepsy
KW - Lacosamide
KW - Medication adherence
KW - Mood
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85020736327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020736327&partnerID=8YFLogxK
U2 - 10.1016/j.yebeh.2017.05.001
DO - 10.1016/j.yebeh.2017.05.001
M3 - Article
C2 - 28623755
AN - SCOPUS:85020736327
SN - 1525-5050
VL - 73
SP - 90
EP - 94
JO - Epilepsy and Behavior
JF - Epilepsy and Behavior
ER -